Clinical Trial Update: DAPAgliflozin for Renal Protection in Heart Transplant Recipients [Phase 3]

View source ↗

Summary

Phase 3 clinical trial assessing renal protection with DAPAgliflozin in heart transplant recipients, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Heart Failure

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: Oslo University Hospital | Conditions: Heart Transplant Failure, Kidney Failure | Phase 3 | Status: RECRUITING